FIELD: medicine.
SUBSTANCE: antibody and its fragment that bind to the phospho-epitope on the Tau protein, as well as the polynucleotides encoding them, are provided; cell lines that produce antibodies; a vector, its host cell and a method for production of the antibody and its functional fragment are proposed. In addition, a pharmaceutical composition, a method for treatment, alleviation or protection against taupathy; a method for induction of a passive immune response in an animal; a method for diagnosis of a protein tau-related disease, disorder or condition, or a predisposition to a protein tau-related disease; a method for monitoring of a minimal residual disease in a patient after treatment with an anti-tau antibody; a method for prediction of patient's response to treatment with an anti-tau antibody; methods for detection of phospho-Tau multimers (pTau) in a brain sample, including postmortem detection; a diagnostic set are proposed.
EFFECT: invention can find further application in the diagnosis and therapy of diseases associated with Tau-protein.
42 cl, 10 dwg, 15 tbl, 11 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2603078C2 |
PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2582916C2 |
HUMANIZED TAU-ANTIBODY | 2013 |
|
RU2644242C2 |
ANTIBODIES, SPECIFIC TO HYPERPHOSPHORYLATED TAU-PROTEIN, AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2727911C2 |
ANTIBODIES SPECIFIC TO HYPERPHOSPHORYLATED TAU-PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2760875C1 |
MONOCLONAL BODY AGAINST AMYLOID BETA | 2008 |
|
RU2571856C2 |
THERAPY AND DIAGNOSTICS BASED ON PROTEINS OF TAU-MEDIATED PATHOLOGY IN ALZHEIMER DISEASE | 2012 |
|
RU2645259C2 |
ANTI-TAU ANTIBODIES AND METHODS OF USE | 2014 |
|
RU2661111C2 |
THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR DEMENTIA | 2013 |
|
RU2657438C2 |
USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2604181C2 |
Authors
Dates
2017-12-21—Published
2012-10-05—Filed